According to information from the president of the BioCubaFarma group, Eduardo Martinez, this step is the result of bilateral collaboration in the biotechnological sector, specifically between the Center for Genetic Engineering and Biotechnology (CIGB), and a facility opened in the city of Yongzhou, Hunan province.

In his official Twitter account, he stressed that this joint research is aimed at achieving effective vaccines against coronaviruses and would not only have value in the current pandemic, but could also be effective against the emergence of new pathogens belonging to this family of viruses.

During an interview with the Chinese news agency Xinhua, the director of Biomedical Research of the CIGB, Gerardo Guillen, explained that the project arose at the request of the Chinese side and has the approval of the Cuban Ministry of Science and Technology.

The vaccine is based on a combination of virus parts that are conserved and not so exposed to variation to generate antibodies, with those directed to cell responses.

Pan-Corona is a recombinant type antigen, which is the vaccine development platform in which the CIGB has the greatest experience, with successful antecedents such as that of hepatitis B, in addition to two of the Cuban vaccines against Covid-19, one of these Abdala.

It is a strategy that could protect against epidemiological emergencies of new strains of coronavirus that could exist in the future’, he said.

pgh/abo/mgt/cdg